Table 4 |
||||||||
|
Number of cancer cases in subjects with residence in the Schiphol area according to site, gender and area of residence, 1988–2003 |
||||||||
|
cancer site (ICD-10 code) and gender |
area of residence |
|||||||
|
|
||||||||
|
ring zone |
core zone |
|||||||
|
|
|
|||||||
|
parameter |
parameter |
|||||||
|
|
|
|||||||
|
number of cases |
SIR# |
95% CI |
number of cases |
SIR# |
95% CI |
RR## |
95% CI |
|
|
|
||||||||
|
All malignancies (C00–C95) |
10 855 |
1.01 |
0.99, 1.03 |
2 352 |
1.06* |
1.02, 1.10 |
1.05* |
1.01, 1.10 |
|
adult males |
5 440 |
0.98 |
0.96, 1.01 |
1 257 |
1.07 |
1.01, 1.13 |
1.09* |
1.03, 1.16 |
|
adult females |
5 356 |
1.03 |
1.00, 1.06 |
1 080 |
1.04 |
0.98, 1.11 |
1.01 |
0.95, 1.08 |
|
children (<15) |
59 |
1.25 |
0.95, 1.61 |
15 |
1.29 |
0.72, 2.13 |
1.04 |
0.59, 1.83 |
|
Head & neck (C00–C14) |
238 |
1.06 |
0.93, 1.21 |
44 |
0.90 |
0.65, 1.21 |
0.85 |
0.61, 1.17 |
|
males |
133 |
0.92 |
0.77, 1.09 |
29 |
0.89 |
0.59, 1.27 |
0.96 |
0.64, 1.44 |
|
females |
105 |
1.32* |
1.08, 1.59 |
15 |
0.93 |
0.52, 1.53 |
0.70 |
0.41, 1.21 |
|
Gastrointestinal tract (C15–C26) |
2 422 |
0.99 |
0.95, 1.03 |
467 |
0.96 |
0.87, 1.05 |
0.97 |
0.88, 1.07 |
|
males |
1 240 |
0.98 |
0.92, 1.03 |
254 |
0.95 |
0.83, 1.07 |
0.97 |
0.85, 1.11 |
|
females |
1 182 |
1.00 |
0.95, 1.06 |
213 |
0.97 |
0.85, 1.11 |
0.97 |
0.84, 1.12 |
|
Respiratory system (C30–C34) |
1 484 |
0.91* |
0.86, 0.96 |
378 |
1.10 |
0.99, 1.22 |
1.21* |
1.08, 1.35 |
|
males |
1 085 |
0.85* |
0.80, 0.90 |
293 |
1.08 |
0.96, 1.21 |
1.27* |
1.12, 1.45 |
|
females |
399 |
1.13* |
1.02, 1.24 |
85 |
1.17 |
0.93, 1.44 |
1.04 |
0.82, 1.31 |
|
Breast (C50) |
1 731 |
1.05* |
1.01, 1.11 |
356 |
1.04 |
0.93, 1.15 |
0.99 |
0.88, 1.11 |
|
Female genital organs (C51–C58) |
567 |
0.93 |
0.86, 1.01 |
143 |
1.16 |
0.98, 1.37 |
1.24* |
1.04, 1.50 |
|
Prostate (C61) |
1 044 |
1.02 |
0.96, 1.08 |
247 |
1.19* |
1.05, 1.35 |
1.17* |
1.02, 1.34 |
|
Bladder & other urinary tract (C65–C68) |
468 |
1.09 |
0.99, 1.19 |
102 |
1.18 |
0.96, 1.43 |
1.16 |
0.93, 1.43 |
|
males |
341 |
1.05 |
0.95, 1.17 |
84 |
1.26* |
1.01, 1.56 |
1.20 |
0.94, 1.52 |
|
females |
100 |
0.93 |
0.76, 1.13 |
18 |
0.92 |
0.54, 1.44 |
0.98 |
0.60, 1.63 |
|
Hematological malignancies (C81–C96) |
855 |
1.10* |
1.03, 1.18 |
189 |
1.17* |
1.01, 1.35 |
1.06 |
0.91, 1.24 |
|
males |
483 |
1.16* |
1.06, 1.27 |
115 |
1.26* |
1.04, 1.51 |
1.09 |
0.89, 1.33 |
|
females |
372 |
1.04 |
0.94, 1.15 |
74 |
1.06 |
0.83, 1.33 |
1.02 |
0.79, 1.31 |
|
Other sites |
2 073 |
1.03 |
0.99, 1.08 |
426 |
1.02 |
0.93, 1.12 |
0.99 |
0.89, 1.10 |
|
males |
1 148 |
1.03 |
0.97, 1.09 |
243 |
1.01 |
0.89, 1.14 |
0.98 |
0.85, 1.12 |
|
females |
925 |
1.03 |
0.97, 1.10 |
183 |
1.04 |
0.90, 1.20 |
1.01 |
0.86, 1.18 |
|
|
||||||||
|
* p < 0.05 # reference population: the Netherlands 1989–2003 ## ratio of the SIR of the core zone and the SIR of the ring zone CI = confidence interval; SIR = standardized incidence ratio; RR = rate ratio |
||||||||
|
Visser et al. BMC Public Health 2005 5:127 doi:10.1186/1471-2458-5-127 |
||||||||
